International Journal of Life science and Pharma Reviews (IJLPR)  
   
 
International Journal of Life science and Pharma Research (IJLPR)
Pharmaceutical Sciences
Volume 11 issue 3, May    Pages:1-6
Impact of Azithromycin and 8-Hydroxychloroquine in 2019 Novel Coronavirus (COVID-19) Pandemic: A Systematic Review

Srikanta Chandra, Preeta Bose, Jyoti Saxena, Muniraj Bhattacharya, Arun dutta, Jyotirmay Samanta and Lucky Mukherjee
[View PDF]
DOI: http://dx.doi.org/10.22376/ijpbs/lpr.2021.11.3.P1-6
Abstract:
As we know novel coronavirus is an emergent nuisance in this stipulated period. Corona virus is a group of enveloped viruses, with non-segmented, single stranded & positive sense RNA genomes. Human Corona virus is mainly subdivided into four categories such as 229E, NL63, OC43, HKU1. Epidemiologically it has a greater prevalence in the modern era. The features encountered in the clinical course of the disease are multifarious spanning from cough, sneezing, fever, breathlessness. It may take 2-14 days for a person to notice symptoms after infection.  Azithromycin and 8 Hydroxychloroquine both   plays an instrumental role for management of COVID-19. Azithromycin is a  macrolide antibiotic   and it  binds with a 50s ribosome  then inhibits  bacterial  protein synthesis. On the other hand 8-Hydroxychloroquine was approved by United State in the year of 1955 .Basically it is used as a antimalarial drugs . Briefly, in inflammatory conditions it binds with toll like receptor & blocks them.  8- hydroxychloroquine   increases  lysosomal pH in antigen presenting cells  . In inflammatory conditions it blocks toll like receptors on plasmacytoid dendritic cells. In our review we focused on  the role of Azithromycin, and 8-hydroxychloroquine in Covid-19 .
Keywords: Coronavirus, COVID-19, HKU1, Azithromycin, Hydroxychloroquine, RNA genomes
 
 
stripe
© 2010-2015 IJLPR. All rights reserved. Specialized online journals by ubijournal. Website by Ubitech Solutions